Loading
A phase 1 trial of PLB-002 run by Primelink BioTherapeitics(ShenZhen) Limited, now recruiting.
A Study of PLB-002 in Advanced Solid Tumors is a phase 1 interventional study registered as NCT07304128 by Primelink BioTherapeitics(ShenZhen) Limited, with 100 participants planned, started 2026-02-06. Conditions recorded: Advanced Solid Tumor. Interventions recorded: PLB-002.
Shares PrimeLink BioTherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PrimeLink BioTherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PrimeLink BioTherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PrimeLink BioTherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PrimeLink BioTherapeutics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/